Evidence map›Paper›PMID 29749395›Full record

Trial reportLeukemia2018

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Guangwu Guo, Noopur S Raje, Charles Seifer, Jake Kloeber, Randi Isenhart, Gavin Ha, Andrew J Yee, Elizabeth K O'Donnell, Yu-Tzu Tai, Paul G Richardson and 15 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Guangwu GuoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Noopur S RajeHarvard Medical School, Boston, MA, USA.
Charles SeiferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jake KloeberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6646-564X
Randi IsenhartDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gavin HaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew J YeeHarvard Medical School, Boston, MA, USA.
Elizabeth K O'DonnellHarvard Medical School, Boston, MA, USA.
Yu-Tzu TaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Paul G RichardsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Giada BianchiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacob P LaubachDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Diane WarrenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Erica GemmeCenter for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA.
Jordan VoisineDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Julia FredeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Antonis KokkalisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Huiyoung YunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Valeriya DimitrovaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tushara VijaykumarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9133-8108
Nikhil C MunshiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kenneth C AndersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Birgit KnoechelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jens G LohrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. jensg_lohr@dfci.harvard.edu.

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI RICHARD YOUNG · 2011 to 2026
$32.5M
Determining the mutational landscape of circulating multiple myeloma cellsK08CA191026 · NCI · DANA-FARBER CANCER INST · PI LOHR, JENS G · 2015 to 2019
$886k
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemiaK08CA191091 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2015 to 2019
$886k
NCI NIH HHS K08 CA191026NCI NIH HHS K08 CA191091NCI NIH HHS P01 CA155258
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clonal EvolutionBiomarkers, TumorCase-Control StudiesCell-Free Nucleic AcidsExome SequencingFollow-Up StudiesHumansMultiple MyelomaSequence Analysis, DNAWhole Genome SequencingBiomarkers, TumorCell-Free Nucleic Acids

Identifiers

PMID29749395
PMCPMC6160352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.